A new study presented at the annual meeting of the European Association for the Study of Diabetes (EASD), being held in Madrid from September 9-13, and published simultaneously in the New England Journal of Medicine (NEJM), has revealed that liraglutide, an anti-obesity drug, is safe and effective in children aged 6-12 years.
The use of GLP-1 analog diabetes drugs-such as semaglutide, sold under the trade name Ozempic-is not linked to an increased risk of suicide, according to two studies published in JAMA Internal Medicine. The first, led by a U.S. team, analyzes data from more than 3,300 people who have participated in clinical trials. The second analyzes data from 124,517 users of these drugs in Sweden and Denmark, and compares them with an even larger group of people who used another type of diabetes medication.
In research using a WHO database of adverse drug reactions, the authors identified a signal of disproportionality of suicidal ideation with semaglutide, one of the drugs used to treat type 2 diabetes and obesity. The study, published in JAMA Network Open, did not find this signal for liraglutide, another drug indicated for these treatments.
A paper published today in the journal Science explores the potential of glucagon-like peptide-1 (GLP-1)-based drugs such as semaglutide to treat diseases beyond diabetes and obesity. For example, recent studies suggest that they could improve conditions ranging from depression to neurological disorders to cardiovascular and kidney disease.
Management of gestational diabetes should include earlier testing during pregnancy, as well as testing in the postpartum period, according to a series of papers published in The Lancet. Screening is usually done during the second half of pregnancy, but the authors note that diagnosis and treatment is especially beneficial before 14 weeks of pregnancy.
Researchers at the University of Hong Kong have analysed data from more than 37,000 patients with type 2 diabetes followed for several years. Although some clinical trials have shown that weight loss can be quite effective in controlling the disease, the study data indicate that in the long term and 'in the real world' this is only achieved in 6% of patients. The results are published in the journal Plos Medicine.
An early first menstrual period (menarche) - compared with the average of 13 years - is associated with an increased risk of type 2 diabetes in women under the age of 65 and also with an increased risk of stroke among those living with diabetes, says a study published in BMJ Nutrition, Prevention & Health. The research analyses data from a national health survey in the US, focusing on women aged 20-65 between 1999 and 2018.
If effective strategies are not developed, more than 1.3 billion people will be living with diabetes by 2050, some 800 million more than today. This is according to the lead study in a set of papers published in The Lancet and The Lancet Diabetes & Endocrinology. In addition, 75% of these people will live in low- and middle-income countries, which is largely due to "structural racism and inequality", according to the editorial accompanying the studies.
Previous research has shown that coffee drinking is associated with a lower risk of cardiovascular disease, but most are short-term, observational studies - they describe associations without being able to determine cause and effect. Research published in BMJ Medicine uses another method (Mendelian randomisation) to study potential causal relationships between caffeine levels in plasma and cardiovascular health, using genetic variants in nearly 10,000 people who participated in long-term studies. Higher genetically-predicted caffeine concentrations in plasma were associated with lower body-mass index and fat mass and a lower risk of type 2 diabetes. In addition, the research shows that 43% of the protective effect of caffeine on the risk of type 2 diabetes was influenced by a reduction in body mass index.